Management of Lower-Risk Myelodysplastic Syndromes
The management of myelodysplastic syndromes is complicated by the generally advanced age of the patients, the non-hematologic comorbidities seen in this cohort, and the relative inability of older patients to tolerate certain intensive forms of therapy. There are limited treatment options for patients with disease progression, especially for those with disease refractory to hypomethylating agents.
  • Myelodysplastic Syndrome
  • Myelodysplastic Syndromes
  • Recorded Webcast
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation